Abstract 2053P
Background
In recent decades, the home care initiative has expanded in the health system, mainly linked to hospitals. The mismatch between available financial resources and advances related to cancer therapy requires projects to improve cost minimization processes.
Methods
The variables collected for each sector were described through monthly totals and averages per year. To verify the existence of an association between expenses with material, medication and chemotherapy and the cost avoided with monthly dehospitalization, Pearson's correlation coefficients and their respective p-values were calculated. Spending on medication and total spending on material, medication and chemotherapy were related to the amount avoided using linear regression models, in order to estimate the effect of increased spending on medication on avoided costs. The same procedure was performed to estimate the effect of increased costs on bed turnover, using linear regressions, and on the number of days of hospitalization avoided per month, using Poisson regression.
Results
Pearson's coefficients confirm a relationship, with a positive sign, between expenses and avoided costs with early dehospitalization, showing a perfect positive relationship between the variables, with a statistically significant p-value. Effect of expenses on total costs with hospitalization avoided on General Hospitalization, Coefficients - Amount spent on medication:100.36; 95% CI (14.26, 186.45); p-value= 0.02. By the linear model, the total avoided cost with discharges was $795,204.52 in the three-year period from 2020 to 2022, for a total of 3,722 avoided hospitalization days and an average cost avoided with discharges of $70,146.06. Effect of expenses on the days of hospitalization avoided (Poisson regression) was statistically significant in all variables (p-value<0.001).
Conclusions
All tests - Pearson Correlation coefficients, Poisson regression, and Generalized Linear Model (p<0.05) confirmed the hypothesis that the discharge managing with outpatient drug release has a significant effect on the final cost avoided with cancer hospitalization.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06